26.1.2007   

EN

Official Journal of the European Union

C 18/2


Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2006 to 31 December 2006

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))

(2007/C 18/02)

—   Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

4.12.2006

Naglazyme

BioMarin Europe Limited

Axtell House

23-24 Warwick Street

London W1B 5NQ

United Kingdom

EU/1/05/324/001

6.12.2006

4.12.2006

Kaletra

Abbott Laboratories Ltd

Queenborough

Kent ME11 5EL

EU/1/01/172/001-005

8.12.2006

11.12.2006

Rotarix

GlaxoSmithKline Biologicals s.a.

rue de l'Institut 89

B-1330 Rixensart

EU/1/05/330/001-004

13.12.2006

18.12.2006

NeoSpect

CIS bio international

Route Nationale 306

Saclay

Boîte Postale 32

F-91192 Gif-sur-Yvette

EU/1/00/154/001-002

21.12.2006

18.12.2006

Viracept

Roche Registration Limited

6 Falcon Way

Shire Park

Welwyn Garden City

AL7 1TW

United Kingdom

EU/1/97/054/003-004

EU/1/97/054/006

20.12.2006

18.12.2006

ATryn

LEO Pharma A/S

Industriparken 55

DK-2750 Ballerup

Genzyme Europe B.V.

Gooimeer 10

1411 DD Naarden

Nederland

EU/1/06/355/001-003

20.12.2006

19.12.2006

SonoVue

Bracco International B.V.

Strawinskylaan 3051

1077ZX Amsterdam

Nederland

EU/1/01/177/001

21.12.2006

—   Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision

Name of the medicinal product

INN

(International Non-Proprietary Name)

Holder of the marketing authorization

Number of the entry in the Community Register

Pharmaceutical form

ATC code

(Anatomical Therapeutic Chemical Code)

Date of notification

18.12.2006

PRAC-TIC

pyriprole

Novartis Sanidad Animal S.L.

Calle de la Marina, 206

E-08013 Barcelona

EU/2/06/066/001-012

Spot-on solution

QP53AX26

20.12.2006

20.12.2006

Medicinal Oxygen Air Liquide Santé

Oxygen

Air Liquide Santé International

10 rue Cognacq-Jay

F-75341 Paris Cedex 07

EU/2/06/067/001-002

Inhalation gas

QV03AN01

22.12.2006

19.12.2006

ProMeris

Metaflumizone

Fort Dodge Animal Health Holland

C.J. van Houtenlaan 36

1381 CP Weesp

Nederland

EU/2/06/064/001-004

Spot-on solution

QP 53AX25

22.12.2006

19.12.2006

ProMeris Duo

Metaflumizone, Amitraz

Fort Dodge Animal Health Holland

C.J. van Houtenlaan 36

1381 CP Weesp

Nederland

EU/2/06/065/001-010

Spot-on solution

QP 53AD51

21.12.2006

—   Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Rejected

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

11.12.2006

Veraflox

Bayer HealthCare AG

D-51368 Leverkusen

-

14.12.2006

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency

7, Westferry Circus, Canary Wharf

London E14 4HB

United Kingdom


(1)  OJ L 136 of 30.4.2004, p. 1.